VEGFA and cancer: The presence of VEGF-A in the examined tumors was confirmed by immunohistochemical staining performed on day ten post injection of [52Mn]Mn-DOTAGA-bevacizumab, and a strong expression was found in the membrane of the cancer cells (Figure 5C) confirming the target-specific property of the radiopharmaceutical.